SuperworthHarrow profit margin HROW
Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.
- Net margin, 12 months
- −13.5%
- Operating margin, 12 months
- −1.0%
- Net margin on a year earlier
- −9.0 pts
- Peer median
- 10.9%
Over the twelve months to Jun 30, 2026, Harrow kept −13.5% of its revenue as net profit, with an operating margin of −1.0% and a gross margin of 73.3%.
Five years earlier its net margin was 12.0%.
The median for 10 large drugmakers of a similar size is 10.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −1.9% | 11.2% | 75.1% |
| FY2024 | −8.8% | 4.4% | 75.3% |
| FY2023 | −18.7% | 0.3% | 69.6% |
| FY2022 | −15.9% | 2.2% | 71.3% |
| FY2021 | −24.8% | 2.2% | 74.9% |
| FY2020 | −6.9% | 0.8% | 70.4% |
| FY2019 | 0.3% | −9.4% | 67.3% |
| FY2018 | 35.4% | −12.6% | 60.1% |
| FY2017 | −44.8% | −45.4% | 49.6% |
| FY2016 | −95.7% | −79.6% | 50.7% |
| FY2015 | n/a | n/a | 46.4% |
| FY2014 | n/a | n/a | 34.2% |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −13.5% | −9.0 pts | −1.0% | |
| Q1 FY26 | −5.6% | +4.6 pts | 7.3% | |
| Q4 FY25 | −1.9% | +6.9 pts | 11.2% | |
| Q3 FY25 | −2.0% | +17.8 pts | 11.1% | |
| Q2 FY25 | −4.5% | +17.3 pts | 6.3% | |
| Q1 FY25 | −10.2% | +12.4 pts | 2.1% | |
| Q4 FY24 | −8.8% | +10.0 pts | 4.4% | |
| Q3 FY24 | −19.8% | −7.3 pts | −5.3% | |
| Q2 FY24 | −21.8% | −5.9 pts | −5.5% | |
| Q1 FY24 | −22.6% | −2.8 pts | −5.6% | |
| Q4 FY23 | −18.7% | −2.9 pts | 0.3% | |
| Q3 FY23 | −12.4% | +13.1 pts | 3.1% |
Against its peers
Companies in Drug Manufacturers - General nearest Harrow's size, closest first, today.
| Company | Profit margin |
|---|---|
| HROWHarrow | −13.5% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| ABUSArbutus Biopharma | 84.2% |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| COLLCollegium Pharmaceutical | 5.9% |
| PAHCPhibro Animal Health | 6.6% |
| ANIPANI Pharmaceuticals | 11.1% |
| CRMDCorMedix | 40.5% |
| ZVRAZevra Therapeutics | 42.8% |
| Peer median | 10.9% |
Where Harrow ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Harrow
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.